Vanguard Capital Wealth Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$299K	Buy	+16,691	New	+$286K	0.35%	76

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Matisse Capital Portland, Oregon $234M AUM 19.72% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

1CP

1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

Vanguard Capital Wealth Advisors's HQL Position: Q2 2020 in Review

Vanguard Capital Wealth Advisors opened a new position in abrdn Life Sciences Investors (HQL) in Q2 2020: 16,691 shares worth $299K. The stake represents 0.35% of the portfolio and ranks #76 among its holdings.

70 funds tracked by Wall St. Rank hold HQL as of Q2 2020.

Vanguard Capital Wealth Advisors held 16,691 shares of abrdn Life Sciences Investors worth $299K as of Q2 2020.
abrdn Life Sciences Investors was a new Vanguard Capital Wealth Advisors position in Q2 2020.
abrdn Life Sciences Investors made up 0.35% of Vanguard Capital Wealth Advisors's portfolio in Q2 2020, its #76 holding.
70 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2020.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q2 2020, filed 5 Aug 2020.